Navigation Links
Medarex Announces 2009 First Quarter Financial Results
Date:4/30/2009

PRINCETON, N.J., April 30 /PRNewswire-FirstCall/ -- Medarex, Inc. (Nasdaq: MEDX) announced today its financial results for the quarter ended March 31, 2009.

Medarex's net loss for the quarter ended March 31, 2009 was $48.6 million, or ($0.38) per share. For the same period in 2008, Medarex's net income of $103.3 million, or $0.81 per share, included a gain of $151.8 million, or $1.19 per share, from the sale of 2.5 million shares of Genmab A/S stock in February 2008. Medarex's net loss for the quarter ended March 31, 2009 included a non-cash charge of $4.9 million, or ($0.04) per share, for stock-based compensation recorded in accordance with FAS 123(R) and a non-cash equity in net loss of affiliate charge of $2.4 million, or ($0.02) per share, related to its share of the net loss of Celldex Therapeutics, Inc. Excluding the impact of these items, Medarex's net loss on a non-GAAP basis for the first quarter of 2009 was $41.3 million, or ($0.32) per share.

Total revenues for the quarter ended March 31, 2009 were $10.8 million as compared to $12.0 million for the same period in 2008.

Research and development expenses for the quarter ended March 31, 2009 decreased by $2.2 million, from $49.3 million in 2008 to $47.1 million in 2009. General and administrative expenses decreased by $1.9 million for the quarter ended March 31, 2009, from $12.4 million in 2008 to $10.5 million in 2009.

Medarex ended the first quarter of 2009 with approximately $322.8 million in cash, cash equivalents and marketable securities. In addition, as of March 31, 2009, the fair market value of Medarex's equity interests in Genmab and Celldex Therapeutics were approximately $85.3 million and approximately $32.3 million, respectively.

"Our first quarter accomplishments and steady progress of key development progra
'/>"/>

SOURCE Medarex, Inc.
Copyright©2009 PR Newswire.
All rights reserved

Page: 1 2 3 4 5 6 7 8 9

Related biology technology :

1. Medarex to Present at Thomas Weisel Partners Healthcare Conference 2007
2. Medarex to Present at the Bear Stearns 20th Annual Healthcare Conference
3. Medarex Announces Extension of Broad Antibody Development Relationship with Centocor
4. Medarex to Present at the A.G. Edwards 2nd Annual Emerging Growth Conference
5. Medarex to Present at the UBS Global Life Sciences Conference
6. Medarex Announces Election of Marc Rubin as New Board Member
7. Medarex to Present at the 26th Annual JPMorgan Healthcare Conference
8. Medarex Announces Completion of Sale of Shares in Genmab A/S
9. Medarex to Announce 2007 Fourth Quarter and Year-End Financial Results on Tuesday, February 26, 2008
10. Medarex to Present at the Susquehanna Financial Group Healthcare Conference
11. Medarex Announces Presentations at Annual Meeting of the American Association for Cancer Research
Post Your Comments:
*Name:
*Comment:
*Email:
(Date:8/26/2015)... , Aug. 26, 2015  Platform therapeutic ... it has received a $1.5M Phase II SBIR ... to further develop its therapeutic agent to reduce ... need in end stage renal disease (ESRD) patients ... National Institute of Diabetes and Digestive and Kidney ...
(Date:8/26/2015)... KONG , Aug. 26, 2015 China ... China,s leading provider of cord ... stem cell storage services, today announced that the Company ... Limited ("MO2"), an entity wholly owned by Mr. Yuen ... Company, has acquired the outstanding shares (the "Shares") of  ...
(Date:8/26/2015)... ... 2015 , ... PRC Clinical, a Clinical Trial Management Expert CRO, ... in southern California. The Clinical Trial Management Expert CRO seeks to introduce more California-based ... , Stem Cell Meeting on the Mesa on October ...
(Date:8/25/2015)... UK (PRWEB) , ... August 25, 2015 , ... ... determining whether breast tissue lesions are cancerous is described by University of Illinois ... international society for optics and photonics. , In “ Breast cancer diagnosis using ...
Breaking Biology Technology:Symic Biomedical Awarded $1.5MM NIH Phase II SBIR Grant to Develop its Proteoglycan Mimetic Therapeutics to Reduce Vascular Access Failures in ESRD 2Symic Biomedical Awarded $1.5MM NIH Phase II SBIR Grant to Develop its Proteoglycan Mimetic Therapeutics to Reduce Vascular Access Failures in ESRD 3China Cord Blood Corporation Receives Notice of Transactions Regarding its 7% Senior Convertible Notes Due 2017 2China Cord Blood Corporation Receives Notice of Transactions Regarding its 7% Senior Convertible Notes Due 2017 3PRC Clinical To Attend Major Industry Conferences And Meet Sponsor Companies In The San Diego Biotech Hub 2PRC Clinical To Attend Major Industry Conferences And Meet Sponsor Companies In The San Diego Biotech Hub 3New Optical Method Promises Faster, More Accurate Diagnosis of Breast Cancer 2New Optical Method Promises Faster, More Accurate Diagnosis of Breast Cancer 3New Optical Method Promises Faster, More Accurate Diagnosis of Breast Cancer 4
... SEATTLE, Nov. 10, 2010 Dendreon Corporation (Nasdaq: ... has completed the submission of the post-approval supplement ... the Morris Plains, New Jersey manufacturing facility. Dendreon ... to manufacture PROVENGE. The standard U.S. Food and ...
... announces that a new stem cell gene and enzyme replacement ... with Tay-Sachs disease on November 2, 2010. Tay-Sachs is a ... heritage and in very rare cases families of Eastern European ... appear normal at birth but about six months of age ...
... SAN DIEGO, Nov. 10, 2010 SG Biofuels , ... Jatropha, today announced it has established a strategic partnership with ... Limited (NYSE: BG ), to research and develop ... SG Biofuels President and Chief Executive Officer ...
Cached Biology Technology:Dendreon Submits Post-Approval Supplement to the PROVENGE Biologics License Application for New Jersey Manufacturing Facility 2Tay-Sachs Disease Stem Cell Gene Enzyme Treatment 2SG Biofuels and Bunge Form Strategic Alliance to Process Jatropha Seeds Into Sustainable Crude Oil 2
(Date:8/6/2015)... Aug. 6, 2015 Synaptics Inc. (NASDAQ: ... interface solutions, today announced collaboration with Microsoft on ... 10. Microsoft leveraged Synaptics, deep expertise in human ... Through stringent testing, Synaptics, advanced ... with Microsoft,s Precision TouchPad (PTP) specification empowering OEMs ...
(Date:8/5/2015)... 2015 Transparency Market Research has ... - Global Industry Analysis, Size, Share, Growth, Trends and ... recognition is forecast to reach US$ 2,671.8 Mn by ... surveillance systems by civil and government agencies. This is ... terrorist activities across the globe that would elevate the ...
(Date:8/4/2015)... DUBLIN , Aug. 04, 2015 /PRNewswire/ ... ( http://www.researchandmarkets.com/research/nvh7k2/digital_forensics ) has announced the addition ... Component (Hardware, Software, and Service), Sub-Segment (Computer ... Cloud Forensics), Tool Types, Service, Vertical and ... report to their offering. By ...
Breaking Biology News(10 mins):Synaptics Chosen for Human Interface Co-Development on Windows 10 2Facial Recognition Market Expected to Reach US$ 2.67 Bn by 2022, at a CAGR of 9.5% From 2015 - 2022: Transparency Market Research 2Facial Recognition Market Expected to Reach US$ 2.67 Bn by 2022, at a CAGR of 9.5% From 2015 - 2022: Transparency Market Research 3Facial Recognition Market Expected to Reach US$ 2.67 Bn by 2022, at a CAGR of 9.5% From 2015 - 2022: Transparency Market Research 4Facial Recognition Market Expected to Reach US$ 2.67 Bn by 2022, at a CAGR of 9.5% From 2015 - 2022: Transparency Market Research 5Facial Recognition Market Expected to Reach US$ 2.67 Bn by 2022, at a CAGR of 9.5% From 2015 - 2022: Transparency Market Research 6Digital Forensics Market - The Market Represents a Compound Annual Growth Rate (CAGR) of 11.3% From 2015 to 2020 2
... A protein known to be overly active in ... to change the structural composition of mammary tissue, potentially ... from the Lombardi Comprehensive Cancer Center at Georgetown University ... Endocrine Society in Washington, DC, the scientists report that ...
... anymore waiting in the dark at this campus bus shelter. ... of engineering researchers at McMaster University has been installed to ... researchers are also hoping that the prototype will help boost ... is located on the west side of University Avenue between ...
... in new grants to study the use and impacts of ... viewed as a worrisome source of water and air pollution ... most important and least publicized environmental issues we face: Escaped ... water, and soil and has huge potential to contribute to ...
Cached Biology News:Protein linked to change in tissue that surround and support breast tumors 2Flexible solar strips light up campus bus shelter 2UC Davis begins $2.8 million in studies of agricultural nitrogen's impacts 2UC Davis begins $2.8 million in studies of agricultural nitrogen's impacts 3
Rabbit polyclonal to ErbB 2 (phospho Y1248) ( Abpromise for all tested applications). entrezGeneID: 2064 SwissProtID: P04626...
...
... Plus Western Blot Strong Antibody Stripping Solution ... Western blots that have been developed with ... It is not recommended for stripping colorimetric ... is not possible to effectively remove substrates ...
... 100 ml supplied as a 5x ... antibodies from membrane-bound proteins without destroying ... chemiluminescent or radioisotopic signals from blots. ... blots. Supplied as a 5X solution ...
Biology Products: